Corpus ID: 5390511

The role of intravenous iron in cancer-related anemia.

@article{Henry2006TheRO,
  title={The role of intravenous iron in cancer-related anemia.},
  author={David H Henry},
  journal={Oncology},
  year={2006},
  volume={20 8 Suppl 6},
  pages={
          21-4
        }
}
  • D. Henry
  • Published 1 July 2006
  • Medicine
  • Oncology
Patients with cancer may have an absolute or functional iron deficiency as a result of their disease or its treatment. These conditions can lead to an insufficient supply of iron for incorporation into erythrocytes during supportive care with erythropoiesis-stimulating proteins for chemotherapy. The use of supplemental iron therapy is well established in patients with chronic kidney disease and anemia, but less well studied in the oncology/hematology setting. Furthermore, the use of oral iron… Expand
Treating the anemic oncology patient with intravenous iron: Why, when, and how?
TLDR
The role of intravenous iron in the management of oncology patients, as well as discussing methods of administration including the use of total-dose infusion regimens, are discussed. Expand
Intravenous Iron Therapy: A Summary of Treatment Options and Review of Guidelines
TLDR
Three intravenous iron products are recommended: low-molecular weight iron dextran (INFeD), ferric gluconate (Ferrlecit), and iron sucrose (Venofer). Expand
Epoetin alfa treatment for patients with chemotherapy-induced anemia.
  • D. Henry
  • Medicine
  • Supportive cancer therapy
  • 2007
TLDR
Recombinant human erythropoietin (epoetin alfa) administered 150 U/kg 3 times weekly or 40,000 U once weekly has been shown in randomized, double-blind, placebo-controlled trials and large, open-label, nonrandomized, community-based studies to effectively and safely correct anemia in patients with cancer undergoing chemotherapy. Expand
Clinical experience with intravenous iron
TLDR
In several published and soon-to-be-published trials comparing adjuvant therapy with intravenous and oral iron, without exception intravenous iron improved hemoglobin and hematopoietic responses, shortened times to maximal response, decreased exposure to ESAs and provided huge cost savings. Expand
Improving Hemoglobin Response in Patients With Chemotherapy-Induced Anemia
TLDR
This clinical report will consider the critical issues surrounding CIA and its treatment, including discussions on the following areas: the etiology of chemotherapy-related anemia; • the reasons for inadequate responses to ESAs; • recent studies on the safe use of ESA therapy and the impact on an anemia treatment paradigm; and • the role of intravenous iron in optimizing response to ESA therapy in patients with CIA. Expand
Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study
TLDR
The Hb increase and response rate were significantly greater with the addition of intravenous iron to epoetin treatment in iron-replete patients and a lower dose of epoETin was required. Expand
Safety and Efficacy of Intravenous Ferric Carboxymaltose (750 mg) in the Treatment of Iron Deficiency Anemia: Two Randomized, Controlled Trials
TLDR
Intravenous FCM is safe, well tolerated, and associated with improvements in hemoglobin and iron indices comparable to SMC when administered in single doses of up to 750’mg at a rate of 100 mg/min. Expand
Efficacy and safety of iron isomaltoside (Monofer®) in the management of patients with iron deficiency anemia
TLDR
Clinical trials and observational studies of iron isomaltoside show that it is an effective and well-tolerated treatment of anemia across different therapeutic areas with a favorable safety profile. Expand
Safety of intravenous iron use in chronic kidney disease
TLDR
There is a need for better understanding and definition of the nature of i.v. iron reactions, as many are nonserious infusion reactions rather than true anaphylaxis, and the importance of reanalysing data using fatalities or standardized terms as outcome measures is suggested. Expand
Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia.
TLDR
In patients with CAA, addition of IV ferric gluconate to darbepoetin failed to provide additional benefit compared with oral iron or oral placebo. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 40 REFERENCES
Supplemental Iron: A Key to Optimizing the Response of Cancer-Related Anemia to rHuEPO?
  • Henry
  • Medicine
  • The oncologist
  • 1998
TLDR
It is important to monitor iron status and to address either true or functional iron deficiency prior to and during rHuEPO therapy to optimize the effect of rHu EPO in cancer patients. Expand
Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial.
  • M. Auerbach, H. Ballard, +6 authors J. Rana
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2004
PURPOSE Recombinant human erythropoietin (rHuEPO) is the standard of care for patients with chemotherapy-related anemia. Intravenous (IV) iron improves hemoglobin (Hb) response and decreases dosageExpand
Intravenous Ferric Gluconate (FG) for Increasing Response to Epoetin (EPO) in Patients with Anemia of Cancer Chemotherapy - Results of a Multicenter, Randomized Trial.
TLDR
FG allows the least iron restricted hematopoiesis and the best Hb responses, especially in patients with TSAT 100, typical of anemia of chronic disease, as well as in evaluable patients who received IV FG versus oral iron or no iron. Expand
Chemotherapy-induced anemia in adults: incidence and treatment.
TLDR
Perceptions by oncologists and patients that lesser degrees of anemia must be endured without treatment may be overcome as greater emphasis is placed on the QOL of the oncology patient and as research provides further insights into the relationships between hemoglobin levels, patient well-being, and symptoms. Expand
Detecting iron deficiency in anemic patients with concomitant medical problems
TLDR
In a population of anemic veterans with a wide variety of concomitant medical problems, a serum ferritin level ≤ 100 µg/L was optimal for determining iron deficiency. Expand
Assessment of hematologic effects and fatigue in cancer patients with chemotherapy-induced anemia given darbepoetin alfa every two weeks.
TLDR
Experience to date with an every-2-week regimen of darbepoetin alfa indicated efficacy comparable to historical experience with weekly and 3-times-weekly regimens of epoetIn alfa in treating chemotherapy-induced anemia in cancer subjects. Expand
Biochemical markers and hematologic indices in the diagnosis of functional iron deficiency.
TLDR
In APR patients, biochemical markers demonstrate weaknesses in the diagnosis of functional ID as defined by hematologic indices, and use of diagnostic plots to illustrate the relationship between the sTfR-F index and CHr allows the progression of ID to be identified, regardless of whether an APR is present. Expand
Parenteral iron therapy options
TLDR
The increased availability of multiple parenteral iron preparations should decrease the need to use red cell transfusions in patients with iron‐deficiency anemia. Expand
Catalytically active iron and bacterial growth in serum of haemodialysis patients after i.v. iron-saccharate administration.
TLDR
It is indicated that 100 mg of iron saccharate often leads to transferrin oversaturation and the presence of catalytically active iron within 3.5 h after i.v. iron injection, and it may be recommendable to use dosage regimens for i.V. iron that would not cause transferrin Oversaturation. Expand
Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology.
TLDR
It is recommended that physicians initiate conventional therapy and observe hematologic response before considering use of epoetin for anemic patients withHematologic malignancies. Expand
...
1
2
3
4
...